New daily pill shows promise in early breast cancer trial

NCT ID NCT03850873

Completed Disease control Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a new daily pill called TQB3616 in 40 adults with advanced breast cancer that had stopped responding to standard hormone therapy. The pill works by blocking a protein that helps cancer cells multiply. The main goals were to find a safe dose and understand how the body processes the drug.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BREAST CANCER

Contacts and locations

Show contact details

Locations

Fifth Medical Center of Chinese People's Liberation Army General Hospital

Beijing, Beijing Municipality, 100039, China
Henan Cancer Hospital

Zhengzhou, Henan, 45008, China
Jiangsu Province Hospital

Nanjing, Jiangsu, 212028, China
The Fourth Hospital of Hebei Medical University and Hebei

Shijiazhuang, Hebei, 050011, China